Table 1
From: Clinical and functional effectiveness of anti-TNF therapy in patients with rheumatoid arthritis
BASAL | 12 MONTHS (p basal-12M) | 24 MONTHS (p 12M-24M) | |
|---|---|---|---|
EVA (mm) | |||
-Etanercept | 72,21±16,78 | 33,20 ± 20,05 (p<0,005) | 31,95 ± 27,12 (p=0,39) |
-Adalimumab | 69,83±20,54 | 45,00 ± 28,33 (p=0,21) | 51,00 ± 28,44 (p=0,16) |
-Infliximab | 69,78±15,45 | 42,56 ± 23,41 (p=0,015) | 37,71 ± 23,95 (p=0,86) |
DAS28 | |||
-Etanercept | 5,88 ± 1,05 | 2,85 ± 1,16 (p<0,005) | 3,09 ± 1,52 (p=0,98) |
-Adalimumab | 5,73 ± 1,51 | 4,05 ± 2,43 (p=0,011) | 3,90 ± 1,88 (p=0,22) |
-Infliximab | 6,03 ± 1,87 | 4,08 ± 1,61 (p=0,021) | 3,83 ± 1,66 (p=0,91) |
HAQ | |||
-Etanercept | 1,61 ± 0,61 | 0,77 ± 0,64 (p <0,005) | 0,80 ± 0,73 (p = 0,87) |
-Adalimumab | 1,63 ± 0,58 | 1,35 ± 0,63 (p = 0,05) | 1,38 ± 0,70 (p =0,58) |
-Infliximab | 1,45 ± 0,74 | 1,24 ± 0,72 (p = 0,20) | 1,28 ± 0,69 (p = 0,34) |